Clinical Trial

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

Study acronym: VALET-CMV
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-18.
Trial Details
NCT Number NCT07079735
Lead Sponsor Columbia University
Collaborators: Cornell University
Conditions CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
Enrollment 150 participants
Start Date 2025-09-12
Primary Completion 2028-01-17 (estimated)
Study Completion 2029-01-17 (estimated)
Updated on ClinicalTrials.gov 2025-09-25